Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim has made available Striverdi Respimat (olodaterol) Inhalation Spray 5 µg by prescription in pharmacies across the US.
Subscribe to our email newsletter
Striverdi Respimat has been prescribed as a once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema
The drug is a long-acting beta agonist (LABA) delivered via a propellant-free inhaler. It is not indicated for the treatment of acute deteriorations of COPD and also for asthma.
In July 2014, the US Food and Drug Administration (FDA) approved Striverdi Respimat based on data from eight Phase III clinical trials including data from 48-week and six-week duration trials, which involved 4,450 people living with COPD.
The company said that patients involved in the 48-week studies were allowed to continue on their usual care with the exception of LABAs.
Boehringer Ingelheim Pharmaceuticals Marketing senior vice-president Kathleen Dowd said for over a half century, the company has been a leader in discovering and developing new therapies for respiratory diseases.
"We’re proud to build upon our respiratory heritage by bringing Striverdi Respimat to market as a new COPD maintenance treatment option," Dowd said.
"Approximately 15 million Americans have been told by a healthcare provider that they have COPD, and we believe Striverdi Respimat will be a welcome option for providers and patients alike."